54 patents
Utility
GHB Formulation and Method for Its Manufacture
18 Jan 24
The present application relates to GHB formulations and methods for manufacturing the same.
Clark ALLPHIN, Scott BURA
Filed: 25 Sep 23
Utility
Sodium Oxybate to Treat Idiopathic Hypersomnia
21 Dec 23
The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably sodium oxybate.
Franck SKOBIERANDA, Dan CHEN, Amanda Leigh STERKEL
Filed: 8 Oct 21
Utility
Treatment Methods Using GHB
7 Dec 23
Provided herein are methods of treating fibromyalgia, post-traumatic stress disorder, irritable bowel syndrome, and irritable bowel disease in a patient with a slow wave sleep deficit by administering oxybate or a pharmaceutically acceptable salt thereof.
Franck SKOBIERANDA, Mark Toddman KIRBY
Filed: 18 Oct 21
Utility
Euglobulin-based Method for Determining the Biological Activity of Defibrotide
9 Nov 23
It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.
Terenzio IGNONI, Vijay KUMAR, Khalid ISLAM
Filed: 12 Jul 23
Utility
Ras Inhibitors and Methods of Using the Same
26 Oct 23
Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
Andrew BELFIELD, Nicolas Emmanuel Stephane GUISOT, Clifford David JONES, Chiara COLLETTO
Filed: 29 Jan 21
Utility
Defibrotide Treatment for the Prevention of Organ Rejection and Injury
23 Mar 23
The present disclosure provides methods of preventing, lessening the effects, or treating organ injury and/or organ rejection optionally associated with organ transplant comprising administering defibrotide.
Polly Rae PINE, Ranjesh HANVESAKUL
Filed: 16 Apr 21
Utility
Methods for Treating Patients Having Sinusoidal Obstruction Syndrome
16 Mar 23
In various embodiments, the present disclosure teaches methods of treating patients diagnosed as having sinusoidal obstruction syndrome with defibrotide.
Massimo IACOBELLI
Filed: 8 Aug 22
Utility
Gamma-hydroxybutyrate Compositions and Their Use for the Treatment of Disorders
17 Nov 22
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB).
Clark P. ALLPHIN, Gunjan JUNNARKAR, Roman SKOWRONSKI, Cuiping CHEN, Katayoun ZOMORODI, Mark ELLER
Filed: 8 Jul 22
Utility
Method of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transporters
23 Jun 22
One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient.
Mark ELLER
Filed: 27 Dec 21
Utility
Alcohol-resistant Drug Formulations
26 May 22
The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping.
Edwin WALSH, Clark Patrick ALLPHIN
Filed: 11 Feb 22
Utility
Carbamoyl Phenylalaninol Compounds and Uses Thereof
31 Mar 22
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
Fionn Hurley, Lawrence Patrick Carter
Filed: 9 Sep 21
Utility
Devices and Methods for Facilitating and Controlling Use of a Medication
31 Mar 22
A device includes a reservoir configured to store a drug formulation including at least one abuse-preventing additive.
Clark ALLPHIN
Filed: 13 May 21
Utility
Controlled Release Dosage Forms for High Dose, Water Soluble and Hygroscopic Drug Substances
31 Mar 22
Controlled release dosage forms are described herein.
Clark ALLPHIN, James PFEIFFER
Filed: 13 Dec 21
Utility
Chiral Synthesis of Fused Bicyclic Raf Inhibitors
10 Feb 22
The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (% ee).
Andrew BELFIELD, Neil HAWKINS, Steven Christopher GLOSSOP, Jean-François MARGATHE, Clifford David JONES, Chiara COLLETTO
Filed: 28 Jul 21
Utility
Fused Bicyclic Raf Inhibitors and Methods for Use Thereof
3 Feb 22
The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
Andrew BELFIELD, Clifford David JONES, Jean-François MARGATHE, Chiara COLLETTO
Filed: 28 Jul 21
Utility
Treatment of Cataplexy
20 Jan 22
The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Filed: 23 Jul 21
Utility
Methods of Treating Idiopathic Hypersomnia
13 Jan 22
The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).
Franck SKOBIERANDA, Dan CHEN, Amanda Leigh STERKEL, Cuiping CHEN, Patricia CHANDLER
Filed: 22 Feb 21
Utility
Gamma-hydroxybutyrate Compositions and Their Uses for the Treatment of Disorders
6 Jan 22
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB).
Clark P. Allphin, Michael DesJardin
Filed: 20 Sep 21
Utility
Methods of Providing Solriamfetol Therapy to Subjects with Impaired Renal Function
6 Jan 22
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 20 Sep 21
Utility
Euglobulin-based Method for Determining the Biological Activity of Defibrotide
16 Dec 21
It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.
Terenzio IGNONI, Vijay KUMAR, Khalid ISLAM
Filed: 27 Aug 21